INBX revenueQ2 2026$0
- Quarter YoY
- -100.0%
- FY YoY
- +550.0%
INBX revenue was $0 in fiscal Q2 2026 (ended Jun 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $1.30M, up 550.0% from fiscal 2024.
Inhibrx Biosciences Inc. (INBX) financials
For the twelve months ended Jun 30, 2026, Inhibrx Biosciences Inc. reported $0 of revenue and -$138.18M of net income.
- Revenue, TTM
- $0
- Revenue growth, YoY
- -100.0%
- Net income, TTM
- -$138.18M
- Free cash flow, TTM
- -$131.90M
- EPS, diluted, TTM
- -$8.88
- Cash
- $133.34M
- Total debt
- $176.28M
- Market cap
- $1.35B
FY2023FY2025
FY2023FY2025
FY2023FY2025
INBX revenue and earnings growth
INBX net incomeQ2 2026-$36.65M
INBX net income was -$36.65M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$28.65M a year earlier. For the full fiscal 2025 it was -$140.06M, compared with $1.69B in fiscal 2024.
INBX EPSQ2 2026-$2.34
INBX diluted EPS was -$2.34 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$1.85 a year earlier. For the full fiscal 2025 it was -$9.04, compared with $112.62 in fiscal 2024.
INBX free cash flowQ2 2026-$29.92M
INBX free cash flow was -$29.92M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$29.95M a year earlier. For the full fiscal 2025 it was -$129.82M, compared with -$197.01M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue | $1.30M | $200.0K | $1.80M |
| Research and development | $113.03M | $203.74M | $191.64M |
| Selling, general and admin | $23.30M | $127.91M | $29.38M |
| Operating income | -$135.03M | -$331.45M | -$219.22M |
| Interest expense | $12.20M | $13.49M | $31.84M |
| Pre-tax income | -$140.05M | $1.69B | -$239.72M |
| Income tax | $2.0K | $2.0K | $3.0K |
| Net income | -$140.06M | $1.69B | -$241.36M |
| EPS, basic | -$9.04 | $114.01 | -$20.48 |
| EPS, diluted | -$9.04 | $112.62 | -$20.48 |
| Diluted shares | 15.5M | 15.0M | 11.8M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Cash and equivalents | $124.22M | $152.60M | $277.92M |
| Current assets | $132.83M | $160.40M | $295.36M |
| Total assets | $146.48M | $180.77M | $307.89M |
| Current liabilities | $33.80M | $40.73M | $56.31M |
| Long-term debt | $100.56M | $0 | $206.97M |
| Total debt | $100.56M | $0 | $206.97M |
| Total liabilities | $138.49M | $47.18M | $264.39M |
| Shareholders' equity | $7.99M | $133.58M | $43.50M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Operating cash flow | -$129.79M | -$194.41M | -$193.31M |
| Capital expenditures | $31.0K | $2.60M | $4.59M |
| Free cash flow | -$129.82M | -$197.01M | -$197.90M |
| Investing cash flow | -$28.0K | -$2.60M | -$4.59M |
| Financing cash flow | $101.45M | $71.68M | $201.96M |
| Stock-based compensation | $11.14M | $58.52M | $24.85M |
| Depreciation and amortization | $2.48M | $2.29M | $1.19M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
|---|---|---|---|
| Revenue growth, YoY | 550.0% | -88.9% | - |
| Operating margin | -10386.5% | -165724.0% | -12178.9% |
| Net margin | -10773.5% | 843786.0% | -13408.9% |
| Free cash flow margin | -9986.5% | -98503.0% | -10994.6% |
| Return on equity | -1752.2% | 1263.3% | -554.8% |
| Return on assets | -95.6% | 933.6% | -78.4% |
| Current ratio | 3.93 | 3.94 | 5.25 |
| Debt to equity | 12.58 | 0.00 | 4.76 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.30M | $0 | $100.0K | $0 | $100.0K | $0 | $1.63M | $119.0K |
| Research and development | $23.90M | $25.22M | $25.35M | $28.54M | $22.27M | $36.88M | $33.37M | $38.89M | $67.63M | $63.85M | $82.09M | $38.06M |
| Selling, general and admin | $8.25M | $5.71M | $5.57M | $5.28M | $6.42M | $6.02M | $16.66M | $7.90M | $93.37M | $9.97M | $7.83M | $7.89M |
| Operating income | -$32.15M | -$30.93M | -$30.92M | -$33.81M | -$27.39M | -$42.90M | -$49.93M | -$46.80M | -$160.90M | -$73.83M | -$88.29M | -$45.83M |
| Interest expense | $5.69M | $3.51M | $3.19M | $3.18M | $3.14M | $2.69M | $0 | $0 | $5.36M | $8.13M | $8.22M | $8.15M |
| Pre-tax income | -$36.65M | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.86B | -$78.71M | -$91.97M | -$51.79M |
| Income tax | $3.0K | $0 | $0 | $0 | $2.0K | $0 | $0 | $0 | $2.0K | $0 | -$4.0K | $2.0K |
| Net income | -$36.65M | -$33.44M | -$32.83M | -$35.26M | -$28.65M | -$43.31M | -$47.87M | -$43.86M | $1.86B | -$78.71M | -$93.60M | -$51.79M |
| EPS, basic | -$2.34 | -$2.15 | -$2.11 | -$2.28 | -$1.85 | -$2.80 | -$4.48 | -$2.84 | $127.10 | -$5.77 | - | -$4.39 |
| EPS, diluted | -$2.34 | -$2.15 | -$2.11 | -$2.28 | -$1.85 | -$2.80 | -$4.25 | -$2.84 | $125.48 | -$5.77 | - | -$4.39 |
| Diluted shares | 15.7M | 15.6M | - | 15.5M | 15.5M | 15.5M | - | 15.5M | 14.8M | 13.6M | - | 11.8M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $133.34M | $161.66M | $124.22M | $153.09M | $186.57M | $216.52M | $152.60M | $196.33M | $226.86M | $252.48M | $277.92M | $337.33M |
| Current assets | $142.21M | $171.34M | $132.83M | $161.42M | $193.96M | $223.39M | $160.40M | $207.45M | $242.06M | - | $295.36M | - |
| Total assets | $154.22M | $183.97M | $146.48M | $177.47M | $212.12M | $242.64M | $180.77M | $222.56M | $258.42M | - | $307.89M | - |
| Current liabilities | $28.06M | $26.51M | $33.80M | $35.98M | $38.94M | $43.64M | $40.73M | $44.09M | $39.05M | - | $56.31M | - |
| Long-term debt | $176.28M | $174.99M | $100.56M | $99.92M | $99.28M | $98.65M | $0 | $0 | $0 | - | $206.97M | - |
| Total debt | $176.28M | $174.99M | $100.56M | $99.92M | $99.28M | $98.65M | $0 | $0 | $0 | - | $206.97M | - |
| Total liabilities | $207.20M | $205.00M | $138.49M | $140.64M | $143.56M | $148.20M | $47.18M | $44.09M | $39.05M | - | $264.39M | - |
| Shareholders' equity | -$52.98M | -$21.04M | $7.99M | $36.83M | $68.56M | $94.44M | $133.58M | $178.47M | $219.37M | $11.57M | $43.50M | $129.59M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$29.92M | -$38.03M | -$30.12M | -$33.82M | -$29.95M | -$35.90M | -$43.72M | -$30.28M | -$57.36M | -$63.05M | -$56.82M | -$54.24M |
| Capital expenditures | $0 | $0 | $0 | $10.0K | $0 | $21.0K | $16.0K | $247.0K | $1.22M | $1.12M | $3.44M | $811.0K |
| Free cash flow | -$29.92M | -$38.03M | -$30.12M | -$33.83M | -$29.95M | -$35.92M | -$43.74M | -$30.53M | -$58.57M | -$64.17M | -$60.26M | -$55.06M |
| Investing cash flow | $0 | $0 | $0 | -$7.0K | $0 | -$21.0K | -$16.0K | -$247.0K | -$1.22M | -$1.12M | -$3.44M | -$811.0K |
| Financing cash flow | $1.60M | $75.46M | $1.25M | $352.0K | $0 | $99.84M | $0 | $0 | $32.95M | $38.73M | $860.0K | $199.89M |
| Stock-based compensation | $3.10M | $2.65M | $2.74M | $3.17M | $2.77M | $2.45M | $2.98M | $2.96M | $46.17M | $6.40M | $6.43M | $6.53M |
| Depreciation and amortization | $523.0K | $537.0K | $564.0K | $582.0K | $662.0K | $675.0K | $689.0K | $760.0K | $475.0K | $360.0K | $298.0K | $304.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -100.0% | - | -100.0% | - | 1200.0% | - | -93.9% | -100.0% | 233.3% | -100.0% | - | - |
| Operating margin | - | - | - | - | -2106.8% | - | -49928.0% | - | -160898.0% | - | -5403.2% | -38510.1% |
| Net margin | - | - | - | - | -2204.2% | - | -47865.0% | - | 1858011.0% | - | -5728.5% | -43520.2% |
| Free cash flow margin | - | - | - | - | -2304.1% | - | -43736.0% | - | -58573.0% | - | -3688.1% | -46265.5% |
| Current ratio | 5.07 | 6.46 | 3.93 | 4.49 | 4.98 | 5.12 | 3.94 | 4.70 | 6.20 | - | 5.25 | - |
| Debt to equity | - | - | 12.58 | 2.71 | 1.45 | 1.04 | 0.00 | 0.00 | 0.00 | - | 4.76 | - |
Source: XBRL data Inhibrx Biosciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
INBX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| INBX | $0 | -100.0% | -$138.18M | - | $1.35B |
| AMGN | $38.90B | +8.2% | $9.39B | 24.1% | $251.65B |
| GILD | $30.99B | +6.5% | -$3.86B | -12.5% | $210.01B |
| MRNA | $2.52B | +13.1% | -$2.79B | -110.5% | $107.39B |
| ARGX | $4.25B | +88.6% | $1.29B | 30.4% | $59.72B |
| RVMD | $0 | - | -$1.13B | - | $43.29B |
| BIIB | $10.30B | +2.3% | $347.50M | 3.4% | $37.67B |
| BNTX | €2.87B | +4.3% | -€1.14B | -39.6% | $21.98B |
| EXEL | $2.50B | +9.1% | $885.14M | 35.5% | $17.51B |
INBX FAQ
8 questionsWhat is INBX revenue?
Inhibrx Biosciences Inc. (INBX) reported $0 of revenue for the twelve months ended Jun 30, 2026. That is down 100.0% from the year before. Revenue for fiscal 2025 was $1.30M.Is INBX profitable?
No. Inhibrx Biosciences Inc. reported a net loss of $138.18M for the twelve months ended Jun 30, 2026.How much cash and debt does INBX have?
Inhibrx Biosciences Inc. reported $133.34M in cash and cash equivalents and $176.28M of debt on its most recent balance sheet in SEC filings.How fast is INBX revenue growing?
Inhibrx Biosciences Inc.'s revenue changed +550.0% in fiscal 2025, to $1.30M.What is INBX free cash flow?
Inhibrx Biosciences Inc. generated -$131.90M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$131.89M less capital expenditures.What is INBX earnings per share?
Diluted earnings per share were -$8.88 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did INBX last report financial results?
The latest statements here come from Inhibrx Biosciences Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this INBX financial data come from?
Quantisnow builds these statements from the structured XBRL data Inhibrx Biosciences Inc. files with the SEC. It is provided for information only and is not investment advice.